Video

Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product

Author(s):

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Transcript

What can practices do to help manage the possibility of having to stock and manage multiple biosimilars for the same reference product?

Jensen: Unfortunately, I do not see this going away anytime soon until we have some more of that biosimilar parity legislation or more collaboration between health systems and payers on choosing preferred products. Until then, we're going to have to stock whatever biosimilars are covered by the patient's insurance in order to prevent that patient liability.

Related Videos
ATS 2025
Bridgette J. Picou, LVN, ACLPN, The Well Project
Dr Gerard Criner
Emma Achola-Kothari, PhD
Dr Margrit Wiesendanger
2 experts in this video
2 experts in this video
Dr Emma Achola-Kothani
Marla Black Morgan, MD, Phoebe Neurology Associates
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo